Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

• Status: Withdrawn
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Symphogen A/S
• Treatments: Antibodies; Antibodies, Monoclonal; Cetuximab

Criteria

Inclusion and Exclusion criteria have been removed due to Symphogen's business decision to no longer perform the clinical study.